Evidence map›Paper›PMID 25893003›Full record

ArticleFuture virology

Unveiling the roles of HBV polymerase for new antiviral strategies.

Daniel N Clark, Jianming Hu

Abstract read
In one paragraph

Article in Future virology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. [Viral hepatitis A to E: prevalence, pathogen characteristics, and pathogenesis].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2022
    Review
  13. Article
  14. Review
  15. Article
  16. Recent Advances in Hepatitis B Treatment.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Daniel N ClarkThe Pennsylvania State University College of Medicine, Milton S Hershey Medical Center, PA 17033, USA.
Jianming HuThe Pennsylvania State University College of Medicine, Milton S Hershey Medical Center, PA 17033, USA.

Funding

MECHANISMS OF HEPADNAVIRUS ASSEMBLY AND REPLICATIONR01AI043453 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI HU, JIANMING · 1999 to 2017
$5.9M
VIRUSES AND CANCERT32CA060395 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI MEYERS, CRAIG M · 1994 to 2021
$4.3M
Mechanisms of Hepadnavirus Assembly and ReplicationR37AI043453 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI Jianming Hu · 2018 to 2026
$3.8M
Molecular Mechanism of Hepadnavirus PersistenceR01AI074982 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI HU, JIANMING · 2008 to 2012
$1.5M
NCI NIH HHS T32 CA060395NIAID NIH HHS R01 AI043453NIAID NIH HHS R01 AI074982NIAID NIH HHS R37 AI043453
6 · The paper itself

Abstract

Infection with HBV is common worldwide, with over 350 million chronic carriers. Chronic HBV infection is associated with cirrhosis and hepatocellular carcinoma. All currently available oral antivirals are directed against the HBV polymerase enzyme, a reverse transcriptase. HBV polymerase contains several important domains and motifs which define its functions and reveal ways to further target it. This enzyme executes many functions required for the HBV replication cycle, including viral RNA binding, RNA packaging, protein priming, template switching, DNA synthesis and RNA degradation. In addition, HBV polymerase must interact with host proteins for its functions. Future therapeutics may inhibit not only the DNA synthesis steps which are carried out by the reverse transcriptase domain (as all current antivirals do) but other domains, functions and interactions which are essential to the HBV replication cycle.

Indexed as

antiviral targetsdrug resistanceHBVreplication cyclereverse transcriptase

Identifiers

PMID25893003
PMCPMC4399241

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.